GlassScriptPhysician profile
Christopher Sott Bryant
NPI 1801836366
$28,313.00
in general payments reported to CMS, 2019-2025
32 companies · $165 in 2025
The $165 reported for 2025 was less than what a typical Gynecologic Oncology provider received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18K · 2020: $4,899 · 2021: $171 · 2022: $419 · 2023: $4,991 · 2024: $127 · 2025: $165.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,463 · Food and Beverage: $820.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,462.50 |
| Food and Beverage | $820.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aspira Women'S Health INC | $20,869.78 | 2019-2020 | |
| Momentis Surgical INC. | $5,018.13 | 2022-2023 | Anovo Surgical System |
| Intuitive Surgical, INC. | $380.50 | 2019-2021 | |
| Abbvie INC. | $268.15 | 2019-2025 | |
| Ethicon INC. | $264.05 | 2022-2023 | Stratafix |
| Tesaro, INC. | $189.01 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $136.31 | 2019-2020 | |
| Medical Device Business Services, INC. | $129.48 | 2025 | Vistaseal |
| Hologic Sales and Service, LLC | $125.41 | 2019 | |
| Gauss Surgical INC. | $97.91 | 2019 | |
| Smith+Nephew, INC. | $97.69 | 2019 | |
| Merck Sharp & Dohme LLC | $77.32 | 2019-2024 | Keytruda |
| Genentech USA, INC. | $64.49 | 2019 | |
| Procept Biorobotics Corporation | $60.87 | 2020 | |
| Astellas Pharma US INC | $60.43 | 2019-2024 | Veozah |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Applied Medical Resources Corporation | $50.84 | 2020 | |
| Pfizer INC. | $49.63 | 2024 | |
| Eisai INC. | $45.70 | 2019-2020 | |
| Daiichi Sankyo INC. | $43.30 | 2019-2021 | |
| Clovis Oncology, INC. | $34.54 | 2019-2020 | |
| Tersera Therapeutics LLC | $32.46 | 2019 | |
| Davol INC. | $29.19 | 2024 | Arista Ah Flexitip |
| Glaxosmithkline, LLC. | $28.51 | 2023 | Zejula, Jemperli |
| Cumberland Pharmaceuticals, INC. | $23.23 | 2019 | |
| Boston Scientific Corporation | $21.88 | 2023 | Upsylon |
| Myriad Genetic Laboratories, INC. | $20.05 | 2023 | Precisetumor |
| Seagen INC. | $18.86 | 2022 | |
| Mimedx Group, INC. | $16.12 | 2025 | |
| Kyowa Kirin, INC. | $16.03 | 2019 | |
| Olympus America INC. | $15.82 | 2023 | Olympus |
| Bolder Surgical LLC | $14.68 | 2021 | |
| Amgen INC. | $12.63 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Bryant listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.